.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB14_Valganciclovir.Valganciclovir

Information

Valganciclovir is an oral prodrug of ganciclovir, an antiviral agent used to treat cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as organ transplant recipients and those with HIV/AIDS. It is currently approved and widely used for CMV prophylaxis and treatment.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers (median age 26 years), following a single oral dose of valganciclovir, under fasting conditions.

References

1. Nguyen, T, et al., & Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02254-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318012

2. Perrottet, N, et al., & Buclin, T (2009). Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrobial agents and chemotherapy 53(7) 3017–3023. DOI:10.1128/AAC.00836-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19307355

3. Vezina, HE, et al., & Balfour, HH (2014). Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. British journal of clinical pharmacology 78(2) 343–352. DOI:10.1111/bcp.12343 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24528138

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)